Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.05. | AcouSort AB: AcouSort AB - Interim Report for the period January - March 2025 | 47 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
First quarter 2025 for the GroupNet sales amounted to TSEK 1,595 (1,357)Result before tax amounted... ► Artikel lesen | |
09.04. | AcouSort AB: Bulletin from the Extraordinary General Meeting of AcouSort AB (publ) | 97 | GlobeNewswire (Europe) | The following resolutions were passed at the Extraordinary General Meeting (the "EGM") of AcouSort AB (publ) (the "Company") on 9 April 2025 in Lund.
Rights issue of sharesThe EGM resolved to approve... ► Artikel lesen | |
09.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 | 142 | Xetra Newsboard | Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON... ► Artikel lesen | |
26.03. | AcouSort AB: AcouSort's CEO answers questions about the company's rights issue and gives his view on the future | 140 | GlobeNewswire (Europe) | In connection with AcouSort's announcement of its plan to carry out a rights issue, several shareholders have contacted the company with questions regarding both the issue itself and how the management... ► Artikel lesen | |
19.03. | AcouSort AB: AcouSort in new collaboration to improve sepsis treatment | 190 | GlobeNewswire (Europe) | AcouSort's business strategy relies on early development collaborations to integrate its separation technology in partnering companies' products and systems. The most recent collaboration of this kind... ► Artikel lesen | |
03.03. | AcouSort AB: AcouSort and Bio-ReCell enter collaboration | 141 | GlobeNewswire (Europe) | AcouSort AB ("AcouSort") and Bio-ReCell Ltd ("Bio-ReCell") announce that the two companies have signed a Letter of Intent to jointly explore developing a system for automated clean-up and isolation... ► Artikel lesen | |
ACOUSORT Aktie jetzt für 0€ handeln | |||||
14.02. | AcouSort AB: Year end report for AcouSort AB 1 January - 31 December 2024 | 70 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037
Fourth quarter for the GroupNet sales amounted to TSEK 1,221 (0)Result before tax amounted to... ► Artikel lesen | |
27.11.24 | AcouSort AB: AcouSort AB - Interim Report for the period July - September 2024 | 118 | GlobeNewswire (Europe) | Summary of the interim report
Significant events during the third quarterOn July 12, AcouSort announces that the Company and GenSensor will collaborate to combine AcouSort's acoustofluidics technology... ► Artikel lesen | |
28.08.24 | AcouSort AB: AcouSort AB - Interim Report for the period April - June 2024 | 95 | GlobeNewswire (Europe) | Summary of the report
Second quarter 2024 for the GroupNet sales amounted to TSEK 961 (1,816)Result before tax amounted to TSEK -4,714 (-3,193)Result per share* was SEK -0.32 (-0.24)Equity ratio** amounted... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVONESIS | 65,38 | +0,68 % | Novonesis (Novozymes A/S): Major shareholder announcement | ||
BIOCRYST PHARMACEUTICALS | 8,834 | -1,63 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
SARTORIUS STEDIM BIOTECH | 203,00 | -0,15 % | UBS stuft Sartorius Stedim Biotech auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Sartorius Stedim Biotech von 244 auf 220 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Matthew Weston passte seine... ► Artikel lesen | |
VBI VACCINES | 0,085 | 0,00 % | VBI Vaccines Inc/BC - 8-K, Current Report | ||
ADMA BIOLOGICS | 21,620 | 0,00 % | ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold? | ||
GLYCOMIMETICS | 0,139 | 0,00 % | GLYCOMIMETICS INC - 8-K, Current Report | ||
BIOLIFE SOLUTIONS | 19,600 | -3,92 % | BioLife Solutions, Inc.: BioLife Solutions Reports First Quarter 2025 Financial Results | Cell Processing revenue of $21.6 million, up 33% over Q1 2024
GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66%
GAAP net loss of $0.4 million and... ► Artikel lesen | |
BIONTECH | 91,45 | +0,77 % | BioNTech-Milliarden-Deal Vorlage für BioNxt Solutions? Bayer-Aktie mit Kaufempfehlung! | Der Milliarden-Deal von BioNTech und Bristol-Myers Squibb war ein echter Paukenschlag und hat die Biotech-Branche wieder wach geküsst. Während Analysten ihr Kursziel für den deutschen Biotech-Überflieger... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,770 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
CUREVAC | 4,668 | -2,95 % | MIDDAY BRIEFING - Unternehmen und Märkte: AIRBUS, DEUTSCHE BANK, RWE, BIONTECH/CUREVAC, BRAINLAB, SCHAEFFLER, BOEING/AIR INDIA, CREDIT AGRICOLE, GSK, RECKITT BENCKISER | DJ MIDDAY BRIEFING - Unternehmen und Märkte
Der Markt-Überblick am Mittag, zusammengestellt von Dow Jones Newswires:
+++++ FEIERTAGSHINWEIS +++++
DONNERSTAG: In Moskau pausiert... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,180 | 0,00 % | Insmed surges on lung drug data; Recursion cuts staff | ||
SUMMIT THERAPEUTICS | 20,125 | 0,00 % | Why Summit Therapeutics Stock Tanked Today | ||
AVIDITY BIOSCIENCES | 32,105 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
EVOTEC | 7,412 | -2,47 % | Evotec-Aktie mit leichten Kursgewinnen (7,024 €) | An der deutschen Börse notiert der Anteilsschein von Evotec gegenwärtig etwas fester. Der jüngste Kurs betrug 7,02 Euro. Für der Anteilsschein von Evotec steht gegenwärtig ein Kursplus 0,43 Prozent... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 44,050 | 0,00 % | MoonLake Immunotherapeutics - 8-K, Current Report |